Business Context and Reporting Period
This Form 8-K Current Report was filed by Karyopharm Therapeutics Inc. on November 25, 2020. The report discloses corporate governance changes, specifically the election of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Composition: The Board of Directors increased its size from eight to nine members.
- Director Election: Chen Schor, 48, was elected as a Class II director. His term expires at the 2021 annual meeting of stockholders.
- Class II Directors: The number of Class II directors increased from two to three.
Compensation and Governance Details
In connection with his election, Mr. Schor received the following compensatory arrangements:
- Cash Retainer: An annual cash retainer of $50,000, prorated based on the effective date of appointment.
- Stock Option: An option to purchase 32,800 shares of common stock at the closing price on the grant date.
- Vesting Schedule: One-third of the shares vest on the first anniversary of the grant date; the remaining shares vest monthly (1/36th per month) over the subsequent two years, contingent on continued service.
- Indemnification: The Company entered into a standard indemnification agreement covering legal expenses and liabilities arising from his service.
Mr. Schor was not appointed to any Board committees at the time of this filing.
Investor Verification Checklist
- Verify the total number of outstanding shares and the dilution impact of the 32,800 new stock options granted.
- Confirm the closing stock price on November 25, 2020, to determine the exercise price of the granted options.
- Review the Company's proxy statement for the 2021 annual meeting to confirm Mr. Schor's re-election status.
- Check for any subsequent committee appointments for Mr. Schor not disclosed in this initial filing.